OptiNose's novel intranasal sumatriptan product highly effective in treating migraines
Wednesday, April 7, 2010 - 13:49
in Health & Medicine
Oslo, April 7, 2010: OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.